GLP-1 agonists in heart failure
Studies of GLP-1 receptor agonists such as semaglutide in patients with heart failure.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 14, 11, 14, 24, 26.
New guidelines and consensus this year
- ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic SyndromeJ Am Soc Nephrol2026 Oct 1
- Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney Int2026 Jun
- Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT)Diabetol Metab Syndr2026 Apr 12
- Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJACC Heart Fail2026 Apr
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE ApproachObesity (Silver Spring)2026 Apr
All papers from the last 12 months
591 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetesJ Diabetes Metab Disord2026 DecPMID 42840232
- Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral centerAm J Prev Cardiol2026 DecPMID 42827863
- Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026Obes Pillars2026 DecPMID 42729919Review
- Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort studyInt J Cardiol2026 Dec 1PMID 42710812
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsCurr Opin Nephrol Hypertens2026 Nov 1PMID 42683763Review
- From adiposity to multisystem morbidity: the case for weight loss as disease modificationLancet Diabetes Endocrinol2026 NovPMID 42660161Review
- Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial EmulationDiabetes Obes Metab2026 NovPMID 42642357
- From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic frameworkCurr Probl Cardiol2026 NovPMID 42586458Systematic review
- Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database StudyDiabetes Obes Metab2026 NovPMID 42581431
- Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and ObesityJ Cardiothorac Vasc Anesth2026 NovPMID 42580924Review
More cardiology trends
All specialties →Coronary drug-coated balloons
Balloons coated with an antiproliferative drug, used in coronary arteries.
Photon-counting CT
A newer CT detector technology, studied for cardiac and coronary imaging.
Conduction system pacing
Pacing the heart's own conduction system, such as the left bundle branch area.
Key point: Conduction system pacing may offer potential advantages over biventricular pacing in patients indicated for CRT; confirmation in larger randomized clinical trials is required.
Cardio-oncology
Heart care for people with cancer, including cardiotoxicity from cancer treatment.
Clonal hematopoiesis (CHIP) and heart disease
Age-related acquired mutations in blood-forming stem cells (CHIP) and their link to cardiovascular disease.
Lipoprotein(a)
A genetically determined lipoprotein linked to atherosclerotic disease, and the drugs being developed to lower it.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("glucagon-like peptide-1"[tiab] OR GLP-1[tiab] OR semaglutide[tiab] OR liraglutide[tiab]) AND "heart failure"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.